2023-505781-28-00招募中2 期
FILOWM4-WaZaBi: "Open label phase 2 study evaluating the efficacy and tolerance of a zanubrutinib and BGB-11417 combination in patients previously treated for Waldenström macroglobulinemia"
French Innovative Leukemia Organization37 个研究点 分布在 1 个国家目标入组 102 人开始时间: 2024年6月27日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 102
- 试验地点
- 37
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Dr Kamel LARIBI
Scientific
French Innovative Leukemia Organization
研究点 (37)
Loading locations...
相似试验
招募中
1 期
A Phase 1b, Randomized, Open-Label Trial to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB097 in Combination with Pembrolizumab in Melanoma Patients with Primary Resistance to an Anti-PD-1-Containing Immunotherapy (MELODY-1)Advanced Melanoma2023-507377-17-00Microbiotica Limited27
招募中
3 期
Ulcerative Colitis: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects with Moderately to Severely Active Ulcerative ColitisUlcerative Colitis2022-501788-41-00Abbvie Deutschland GmbH & Co. KG40
招募中
2 期
Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 TrialGlioblastomaNCT07263438Centre Hospitalier Universitaire Vaudois59
招募中
2 期
A study to investigate WEF-001 in patients with Advanced KRAS-Mutant Solid Tumours.2024-518644-21-01Auricula Biosciences Inc.27
招募中
1 期
A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75098 Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors2025-523165-19-00BeOne Medicines I GmbH15